Mobilization of Endothelial Progenitor Cells After Implantation of CD34 Antibody-covered Sirolimus-eluting COMBO Stent: Assessment with EPC Colony-forming Assay

Overview

Journal Heart Vessels

Specialty Cardiology & Vascular Diseases

Date 2024 Nov 19

PMID 39560718

Authors

Tianyang Lu

Masashi Sakuma

Ryoichi Sohma

Yasuo Haruyama

Setsu Nishino

Shigeru Toyoda

Teruo Inoue

Affiliations

Soon will be listed here.

Abstract

The COMBO stent is a unique stent on which the CD34 antibody is mounted to capture CD34 + endothelial progenitor cells (EPCs) and from which sirolimus is eluted to suppress neointimal hyperplasia. The COMBO stent aims to induce early re-endothelialization and vascular healing and to prevent restenosis. In the clinical setting, however, the effects of the COMBO stent have not been validated in terms of EPC biology. In this study, we assessed the kinetics of circulating EPCs, not only quantitatively by flow cytometric analysis but also qualitatively by an EPC colony-forming assay, in 25 patients undergoing COMBO stent implantation. Among all patients, flow cytometric analysis indicated that the number of circulating CD34 + /KDR + EPCs did not change after COMBO stent implantation compared with baseline (before stent implantation). The EPC colony-forming assay demonstrated that the number of small-type EPC colonies increased on day 2 (3 [2, 9] to 6 [4, 9]/dish, P = 0.026) and that of large-type EPC colonies more prominently increased on day 2 (1 [0, 4] to 5 [1, 10]/dish, P < 0.001) and day 7 (to 2 [1, 7], P = 0.006) after COMBO stent implantation. Based on the results of optical coherence tomography at 3 months after stent implantation, the patients were divided into two groups: well (uncovered strut ratio < 10%, n = 14) and poor (uncovered strut ratio ≥ 10%, n = 10) stent coverage. Compared with baseline values, the number of large-type EPC colonies increased on day 2 (2.9 ± 0.8 to 7.3 ± 2.0, P = 0.026) and tended to increase on day 7 (6.8 ± 2.0/dish, P = 0.062) after COMBO stent implantation in the well coverage group, while it did not change in the poor coverage group. Thus, the COMBO stent might induce mature EPCs in the circulation, which might be associated with subsequent healing processes in vessel sites with stent-induced injury.

References

Kereiakes D . The TWENTE Trial in Perspective: Stents and Stent Trials in Evolution. JAMA Cardiol. 2017; 2(3):235-237. DOI: 10.1001/jamacardio.2016.5208. View

Costa M, Simon D . Molecular basis of restenosis and drug-eluting stents. Circulation. 2005; 111(17):2257-73. DOI: 10.1161/01.CIR.0000163587.36485.A7. View

Inoue T, Croce K, Morooka T, Sakuma M, Node K, Simon D . Vascular inflammation and repair: implications for re-endothelialization, restenosis, and stent thrombosis. JACC Cardiovasc Interv. 2011; 4(10):1057-66. PMC: 3341937. DOI: 10.1016/j.jcin.2011.05.025. View

Kong D, Melo L, Gnecchi M, Zhang L, Mostoslavsky G, Liew C . Cytokine-induced mobilization of circulating endothelial progenitor cells enhances repair of injured arteries. Circulation. 2004; 110(14):2039-46. DOI: 10.1161/01.CIR.0000143161.01901.BD. View

Inoue T, Sata M, Hikichi Y, Sohma R, Fukuda D, Uchida T . Mobilization of CD34-positive bone marrow-derived cells after coronary stent implantation: impact on restenosis. Circulation. 2007; 115(5):553-61. DOI: 10.1161/CIRCULATIONAHA.106.621714. View

Granada J, Inami S, Aboodi M, Tellez A, Milewski K, Wallace-Bradley D . Development of a novel prohealing stent designed to deliver sirolimus from a biodegradable abluminal matrix. Circ Cardiovasc Interv. 2010; 3(3):257-66. DOI: 10.1161/CIRCINTERVENTIONS.109.919936. View

Haude M, Lee S, Worthley S, Silber S, Verheye S, Erbs S . The REMEDEE trial: a randomized comparison of a combination sirolimus-eluting endothelial progenitor cell capture stent with a paclitaxel-eluting stent. JACC Cardiovasc Interv. 2013; 6(4):334-43. DOI: 10.1016/j.jcin.2012.10.018. View

Jaguszewski M, Aloysius R, Wang W, Bezerra H, Hill J, de Winter R . The REMEDEE-OCT Study: An Evaluation of the Bioengineered COMBO Dual-Therapy CD34 Antibody-Covered Sirolimus-Eluting Coronary Stent Compared With a Cobalt-Chromium Everolimus-Eluting Stent in Patients With Acute Coronary Syndromes: Insights From.... JACC Cardiovasc Interv. 2017; 10(5):489-499. DOI: 10.1016/j.jcin.2016.11.040. View

Saito S, Krucoff M, Nakamura S, Mehran R, Maehara A, Al-Khalidi H . Japan-United States of America Harmonized Assessment by Randomized Multicentre Study of OrbusNEich's Combo StEnt (Japan-USA HARMONEE) study: primary results of the pivotal registration study of combined endothelial progenitor cell capture and.... Eur Heart J. 2018; 39(26):2460-2468. PMC: 6037087. DOI: 10.1093/eurheartj/ehy275. View

10.

Woudstra P, Kalkman D, den Heijer P, Menown I, Erglis A, Suryapranata H . 1-Year Results of the REMEDEE Registry: Clinical Outcomes After Deployment of the Abluminal Sirolimus-Coated Bioengineered (Combo) Stent in a Multicenter, Prospective All-Comers Registry. JACC Cardiovasc Interv. 2016; 9(11):1127-34. DOI: 10.1016/j.jcin.2016.02.052. View

11.

Jakobsen L, Christiansen E, Freeman P, Kahlert J, Veien K, Maeng M . Randomized Clinical Comparison of the Dual-Therapy CD34 Antibody-Covered Sirolimus-Eluting Combo Stent With the Sirolimus-Eluting Orsiro Stent in Patients Treated With Percutaneous Coronary Intervention: The SORT OUT X Trial. Circulation. 2021; 143(22):2155-2165. DOI: 10.1161/CIRCULATIONAHA.120.052766. View

12.

Hill J, Zalos G, Halcox J, Schenke W, Waclawiw M, Quyyumi A . Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med. 2003; 348(7):593-600. DOI: 10.1056/NEJMoa022287. View

13.

Masuda H, Alev C, Akimaru H, Ito R, Shizuno T, Kobori M . Methodological development of a clonogenic assay to determine endothelial progenitor cell potential. Circ Res. 2011; 109(1):20-37. DOI: 10.1161/CIRCRESAHA.110.231837. View

14.

Fujii K, Kubo T, Otake H, Nakazawa G, Sonoda S, Hibi K . Expert consensus statement for quantitative measurement and morphological assessment of optical coherence tomography: update 2022. Cardiovasc Interv Ther. 2022; 37(2):248-254. DOI: 10.1007/s12928-022-00845-3. View

15.

Kubo T, Ino Y, Shiono Y, Terada K, Emori H, Higashioka D . Usefulness of optical coherence tomography with angiographic coregistration in the guidance of coronary stent implantation. Heart Vessels. 2021; 37(2):200-207. DOI: 10.1007/s00380-021-01911-1. View

16.

Amano H, Kojima Y, Hirano S, Oka Y, Aikawa H, Matsumoto S . Healed neointima of in-stent restenosis lesions in patients with stable angina pectoris: an intracoronary optical coherence tomography study. Heart Vessels. 2022; 37(7):1097-1105. DOI: 10.1007/s00380-021-02010-x. View

17.

Umemura T, Soga J, Hidaka T, Takemoto H, Nakamura S, Jitsuiki D . Aging and hypertension are independent risk factors for reduced number of circulating endothelial progenitor cells. Am J Hypertens. 2008; 21(11):1203-9. DOI: 10.1038/ajh.2008.278. View

18.

Maroun-Eid C, Ortega-Hernandez A, Modrego J, Abad-Cardiel M, Garcia-Donaire J, Reinares L . Effect of intensive multifactorial treatment on vascular progenitor cells in hypertensive patients. PLoS One. 2018; 13(1):e0190494. PMC: 5755814. DOI: 10.1371/journal.pone.0190494. View

19.

Obi S, Masuda H, Akimaru H, Shizuno T, Yamamoto K, Ando J . Dextran induces differentiation of circulating endothelial progenitor cells. Physiol Rep. 2014; 2(3):e00261. PMC: 4002241. DOI: 10.1002/phy2.261. View

20.

Tsukada S, Kwon S, Matsuda T, Jung S, Lee J, Lee S . Identification of mouse colony-forming endothelial progenitor cells for postnatal neovascularization: a novel insight highlighted by new mouse colony-forming assay. Stem Cell Res Ther. 2013; 4(1):20. PMC: 3706928. DOI: 10.1186/scrt168. View